Business context and reporting period
This summary is based on the supplied Form 10-Q for the three months ended March 31, 2013. The filing identifies the registrant as Access Pharmaceuticals, Inc., not Abeona Therapeutics Inc.; verify that this is the intended filing. Access described itself as an emerging biopharmaceutical company. Its marketed product was MuGard for oral mucositis; ProLindac was in Phase 2, while other drug-delivery programs were preclinical.
Financial performance and liquidity
| Metric | Q1 2013 | Q1 2012 |
|---|---|---|
| Total revenue | $1.224 million | $1.837 million |
| Operating expenses | $1.727 million | $2.526 million |
| Operating loss | $503,000 | $689,000 |
| Net income (loss) attributable to common stockholders | $3.354 million | ($5.332 million) |
| Operating cash flow | ($346,000) | ($1.082 million) |
- MuGard U.S. product sales were $1.162 million, up 110% from $554,000; product costs were $65,000. Product gross contribution was approximately $1.097 million, or 94% of sales.
- Cash and cash equivalents were $50,000 at March 31, down from $396,000 at year-end. Management reported quarterly net cash burn of approximately $160,000 per month.
- Working capital deficit was $6.072 million, up $1.124 million from December 31, 2012. Total liabilities were $15.327 million; stockholders’ deficit was $13.606 million. The filing says the $2.75 million secured note was paid off in November 2012.
- Accumulated deficit was $264.618 million. The filing does not provide a clear conventional operating margin discussion; reported operating loss was $503,000.
Material changes versus the prior period
- Total revenue fell 33%, mainly because Q1 2012 included $706,000 of previously deferred European MuGard license fees and a $500,000 termination fee. Q1 2013 license revenue was $62,000 versus $1.262 million; European MuGard royalties were nil versus $21,000.
- R&D spending declined 57% to $323,000, reflecting reduced staffing and clinical development activity. SG&A declined 20% to $1.338 million, despite higher MuGard selling expenses.
- Common-stockholder income swung to $3.354 million from a $5.332 million loss. This was principally affected by a $4.780 million gain on the preferred-stock derivative liability; the result should not be read as evidence of operating profitability. Q1 2012 also included a $2.316 million warrant-extension expense.
Outlook, risks and unusual items
- Management expected available capital, MuGard sales and anticipated license receipts to fund the current operating level only into the third quarter of 2013, and said additional financing would be needed within twelve months. The filing warns that failure to obtain funds or licensing arrangements could threaten the company’s ability to continue as a going concern; the prior auditor’s report also expressed substantial doubt about going concern.
- Management expected losses for several years. China partners anticipated beginning MuGard sales in Q2 2013; the company was seeking partners for MuGard, ProLindac and its preclinical platforms. No quantitative earnings or revenue guidance was provided.
- Preferred dividends accrued in Q1 were $727,000. Dividends payable totaled $4.256 million at March 31. The company also accrued $857,000 in liquidated damages related to shares not covered by an effective registration statement.
- Derivative fair-value changes materially affected reported earnings: the preferred-stock derivative was a $4.420 million liability at March 31, measured using Level 3 inputs, including a Monte Carlo model and stock-volatility assumptions.
- A purported class action related to Genaera asset transactions remained pending; Access defendants had moved to dismiss, and the company said it would defend the case. The filing disclosed no other material pending legal proceedings.
- Management reported an unremediated material weakness in internal controls due to inadequate monitoring and review of the CFO’s financial-reporting work and lack of segregation of duties. Disclosure controls were deemed ineffective.
Important facts for investors to verify
- Confirm the issuer and filing: the supplied document is for Access Pharmaceuticals, Inc., not Abeona Therapeutics Inc.
- Verify near-term financing, cash runway, and whether the anticipated license receipts and China MuGard launch occurred.
- Assess the quality and sustainability of reported net income, especially the noncash derivative gain and the company’s operating losses and cash burn.
- Review preferred-stock terms, accrued dividends, registration-related damages, derivative valuation assumptions and potential dilution. The filing reports substantial preferred-stock conversion rights and other potentially dilutive securities.
- Check subsequent developments in the Genaera litigation and remediation of the disclosed material weakness.